HEPATO-RENAL SYNDROME: MODERN OPPORTUNITIES OF THERAPY


Cite item

Full Text

Abstract

Aim. Study of efficacy of albimun dialysis with molecular adsorbent recirculation system (MARS) in treatment of type 2 hepatorenal syndrome.
Methods. 25 patients (15 male, 10 female), age 41 - 69 years, with chronic hepatic failure and type 2 hepatorenal syndrome were included into the study. 1st group of patients (n=15) received extended veno-venous haemofiltration and drug treatment, in 2nd group (n=10) albimun dialysis with MARS was also performed.
Results. Drug treatment and extended veno-venous haemofiltration lead to improvement of clinical status, decrease of serum concentration of urea, creatinine, К+, elevation of serum concentration of Na+ and glomerulary filtration rate (GFR). Elevation of systolic blood pressure (SBP) was also observed. In group of patients, who received albimun dialysis with MARS improvement of synthetic function of liver was registered; they also demonstrated higher values of SBP and GFR, than 1st group. 30-day mortality was 73% in 1st group and 40% in 2nd group.
Comclusion. Inclusion into treatment protocol of type 2 hepatorenal syndrome albimun dialysis with MARS leads to improvement of liver synthetic function, decrease of severity of renal failure and 30-day mortality.

References

  1. Dagher L., Moore K. The hepatorenal syndrome. Gut. 2001; 49: 729-737.
  2. Arroyo V., Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Ligt and shadows in an important clinical problem. J. Hepatol. 2000; 32 (Suppl. 1): 157-170.
  3. Mitzner S.T., Klammt S., Perzynski P. et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther. Apher. 2001; 5: 417-422.
  4. Sen S., Williams R., Jalan R. The pathohysiological basis of acute-on-chronic liver failure. Liver. 2002; 22. (Suppl.2): 5-13.
  5. Angeli P., Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J. Hepatol. 2008; 48: 93-103.
  6. Dagher L., Moore K. The hepatorenal syndrome. Gut. 2001; 49: 729- 737.
  7. Salerno F., Gerbes A., Ginès P. et al. Diagnosis, prevention, and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56: 1310- 1318.
  8. Evans T.W. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment. Pharmacol. Ther. 2002; 16: 6-11.
  9. Fernandez J., Navasa M., Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepato-renal syndrome and improves survivsal in cirrhosis. Gastroenterol. 2007; 133: 818-824.
  10. K-U Eckardt, U. Frei (2000) Reversibility of hepatorenal syndrome in an anuric patient with Child C cirrhosis requiring hemodialysis for 7 weeks. Nephrol. Dial. Transplant. 2000; 15: 1063-1065.
  11. Cardenás A. Hepatorenal Syndrome: A dreaded complication of end-stage liver disease. Am. J. Gastroenterol. 2005; 100: 460-467. Ginès P., Guevara M., Arroyo V. et al. Hepatorenal syndrome. Lancet. 2003; 362: 1819-1827.
  12. Mitzner S.T., Stange J., Klammt S. et al. Improvent of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Traspl. 2000; 6: 277-286.
  13. Stange J., Hassanein T.I., Mehta R. et al. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigation, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif. Organs. 2002; 26: 103-110.
  14. Brensing K.A. Textor J., Perz J. et al. Long term outcome after Transjugular intrahepatic portosystemic shunt-shunt in nontransplant cirrhotics with hepatorenal syndrome a phase II study. Gut. 2000; 47: 288 - 295.
  15. Ginés P., Guevara M., Arroyo V. et al. Hepatorenal syndrome. Lancet. 2003; 362: 1819 - 1827.
  16. Dagher L., Moore K. The hepatorenal syndrome. Gut. 2001; 49: 729 - 737.
  17. Moreau R., Durand F., Poynard T. et al. Terlipressin in patients with cirrhosis and type hepatorenal syndrome: a retrospective multicenter study. Gastroenterol. 2002; 122: 923 - 930.
  18. Davenport A. Гепаторенальный синдром. IV Международная конференция «Акт. аспекты экстракорп. очищения крови в интенсив. теp.» 2004: 5 - 13.
  19. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М.: ГЭОТАР-МЕД. 2002.
  20. Brensing K.A. Textor J., Perz J. et al. Long term outcome after Transjugular intrahepatic portosystemic shunt-shunt in nontransplant cirrhotics with hepatorenal syndrome a phase II study. Gut. 2000; 47: 288-295.
  21. Sen S., Davies N.A., Mookerjee R.P. et al. Parhophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized, controlled study. Liver Transpl. 2004; 10: 1109-1119.
  22. Laleman W., Wilmer A., Evenepoel P. Effect of molecular adsorbent recirculation system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Critical Care. 2006; 10: R108-R114

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies